
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News / Financial</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Sat, 16 Jan 2010 22:00:39 EET</pubDate>
<language>en</language>
<item>
<title><![CDATA[Genzyme Reports Fourth-Quarter Revenue]]></title>
<link>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Fourth-Quarter_Revenue/</link>
<comments>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Fourth-Quarter_Revenue/</comments>
<pubDate>Sat, 16 Jan 2010 22:00:39 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Fourth-Quarter_Revenue/</guid>
<description><![CDATA[Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compare<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Strides Arcolab to Collaborate on Generic Products]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_and_Strides_Arcolab_to_Collaborate_on_Generic_Products/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_and_Strides_Arcolab_to_Collaborate_on_Generic_Products/</comments>
<pubDate>Fri, 15 Jan 2010 00:30:11 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_and_Strides_Arcolab_to_Collaborate_on_Generic_Products/</guid>
<description><![CDATA[Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States t<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[PolyMedix Completes $20.7 Million Equity Financing]]></title>
<link>http://www.worldpharmanews.net/Financial/PolyMedix_Completes_20-7_Million_Equity_Financing/</link>
<comments>http://www.worldpharmanews.net/Financial/PolyMedix_Completes_20-7_Million_Equity_Financing/</comments>
<pubDate>Wed, 18 Nov 2009 02:45:12 EET</pubDate>
<dc:creator>Janetvasquez</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/PolyMedix_Completes_20-7_Million_Equity_Financing/</guid>
<description><![CDATA[Funds To Be Used To Continue Development of Two Drug Candidates Into Phase 2 Human Clinical Trials<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed reports continued satisfactory performance in the third quarter 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Nycomed_reports_continued_satisfactory_performance_in_the_third_quarter_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Nycomed_reports_continued_satisfactory_performance_in_the_third_quarter_2009/</comments>
<pubDate>Mon, 16 Nov 2009 02:54:24 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Nycomed_reports_continued_satisfactory_performance_in_the_third_quarter_2009/</guid>
<description><![CDATA[Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilien<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis to expand its human vaccines presence in China]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_to_expand_its_human_vaccines_presence_in_China/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_to_expand_its_human_vaccines_presence_in_China/</comments>
<pubDate>Thu, 12 Nov 2009 01:57:19 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_to_expand_its_human_vaccines_presence_in_China/</guid>
<description><![CDATA[Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis announces USD 1 billion investment to build largest pharmaceutical R&amp;D institute in China]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_announces_USD_1_billion_investment_to_build_largest_pharmaceutical_RD_institute_in_China/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_announces_USD_1_billion_investment_to_build_largest_pharmaceutical_RD_institute_in_China/</comments>
<pubDate>Sat, 07 Nov 2009 00:55:46 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_announces_USD_1_billion_investment_to_build_largest_pharmaceutical_RD_institute_in_China/</guid>
<description><![CDATA[Novartis announced a USD 1 billion investment over the next five years, increasing R&amp;D activities in China and confirming Novartis' long term commitment to China's further economic development, hea<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk increased operating profit by 30% in the first nine months of 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Novo_Nordisk_increased_operating_profit_by_30_in_the_first_nine_months_of_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Novo_Nordisk_increased_operating_profit_by_30_in_the_first_nine_months_of_2009/</comments>
<pubDate>Sun, 01 Nov 2009 01:55:00 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novo_Nordisk_increased_operating_profit_by_30_in_the_first_nine_months_of_2009/</guid>
<description><![CDATA[Sales increased by 15% in Danish kroner and by 11% in local currencies:- Sales of modern insulins increased by 28% (24% in local currencies).- Sales of NovoSeven® increased by 15% (11% in local c<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca PLC Third Quarter &amp; Nine Months Results 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_Third_Quarter__Nine_Months_Results_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_Third_Quarter__Nine_Months_Results_2009/</comments>
<pubDate>Sat, 31 Oct 2009 15:21:35 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_Third_Quarter__Nine_Months_Results_2009/</guid>
<description><![CDATA[Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growt<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis delivers strong new product momentum and operational performance]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_new_product_momentum_and_operational_performance/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_new_product_momentum_and_operational_performance/</comments>
<pubDate>Thu, 29 Oct 2009 01:34:28 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_new_product_momentum_and_operational_performance/</guid>
<description><![CDATA[Novartis maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to USD 11.1 billion as four percentage points of gr<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Merck Revenues Increase by 2.7% to a4 1.9 Billion]]></title>
<link>http://www.worldpharmanews.net/Financial/Merck_Revenues_Increase_by_2-7_to_euro_1-9_Billion/</link>
<comments>http://www.worldpharmanews.net/Financial/Merck_Revenues_Increase_by_2-7_to_euro_1-9_Billion/</comments>
<pubDate>Thu, 29 Oct 2009 01:34:04 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Merck_Revenues_Increase_by_2-7_to_euro_1-9_Billion/</guid>
<description><![CDATA[Merck KGaA announced that Group total revenues rose 2.7% in the third quarter to € 1,944 million from € 1,893 million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bristol-Myers Squibb Achieves Strong Sales]]></title>
<link>http://www.worldpharmanews.net/Financial/Bristol-Myers_Squibb_Achieves_Strong_Sales/</link>
<comments>http://www.worldpharmanews.net/Financial/Bristol-Myers_Squibb_Achieves_Strong_Sales/</comments>
<pubDate>Wed, 28 Oct 2009 03:07:19 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Bristol-Myers_Squibb_Achieves_Strong_Sales/</guid>
<description><![CDATA[Bristol-Myers Squibb posted third quarter 2009 net sales from continuing operations of $5.5 billion, an increase of 4%, or 7% excluding foreign exchange impact, compared to the same period in 2008. G<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Reports Third-Quarter 2009 Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Third-Quarter_2009_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Third-Quarter_2009_Results/</comments>
<pubDate>Sun, 25 Oct 2009 00:20:53 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Third-Quarter_2009_Results/</guid>
<description><![CDATA[Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in the year-ago quarter. Revenues for third-quarte<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Completes Acquisition Of Wyeth]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_Of_Wyeth/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_Of_Wyeth/</comments>
<pubDate>Sat, 17 Oct 2009 13:40:05 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_Of_Wyeth/</guid>
<description><![CDATA[Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merg<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Reports 16.5 Percent Earnings Growth in Third Quarter]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Reports_16-5_Percent_Earnings_Growth_in_Third_Quarter/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Reports_16-5_Percent_Earnings_Growth_in_Third_Quarter/</comments>
<pubDate>Fri, 16 Oct 2009 02:10:20 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Reports_16-5_Percent_Earnings_Growth_in_Third_Quarter/</guid>
<description><![CDATA[Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009. &quot;Abbott is performing well, generating higher-than-expected earnings growth in the third quarter,&quot; s<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott to Acquire Solvay Pharmaceuticals Business]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Solvay_Pharmaceuticals_Business/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Solvay_Pharmaceuticals_Business/</comments>
<pubDate>Wed, 30 Sep 2009 01:09:03 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Solvay_Pharmaceuticals_Business/</guid>
<description><![CDATA[Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and co<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government]]></title>
<link>http://www.worldpharmanews.net/Financial/Sanofi_Pasteur_and_Butantan_Institute_to_Provide_AH1N1_Vaccine_to_Brazilian_Government/</link>
<comments>http://www.worldpharmanews.net/Financial/Sanofi_Pasteur_and_Butantan_Institute_to_Provide_AH1N1_Vaccine_to_Brazilian_Government/</comments>
<pubDate>Sun, 13 Sep 2009 12:59:21 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Sanofi_Pasteur_and_Butantan_Institute_to_Provide_AH1N1_Vaccine_to_Brazilian_Government/</guid>
<description><![CDATA[Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), has signed an agreement with Butantan Institute for the production and supply of a vaccine against the n<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Good first six months in 2009 for Boehringer Ingelheim]]></title>
<link>http://www.worldpharmanews.net/Financial/Good_first_six_months_in_2009_for_Boehringer_Ingelheim/</link>
<comments>http://www.worldpharmanews.net/Financial/Good_first_six_months_in_2009_for_Boehringer_Ingelheim/</comments>
<pubDate>Fri, 31 Jul 2009 01:11:09 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Good_first_six_months_in_2009_for_Boehringer_Ingelheim/</guid>
<description><![CDATA[The pharmaceutical company Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this refl<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott to Acquire Nutrition Businesses, Expanding Presence in India]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Nutrition_Businesses_Expanding_Presence_in_India/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Nutrition_Businesses_Expanding_Presence_in_India/</comments>
<pubDate>Thu, 30 Jul 2009 01:10:48 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_to_Acquire_Nutrition_Businesses_Expanding_Presence_in_India/</guid>
<description><![CDATA[Abbott announced a definitive agreement to acquire the nutrition businesses of Wockhardt Limited, Carol Info Services Limited, and certain Wockhardt subsidiaries and group companies for consideration<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Delivers Solid Second-Quarter Financial Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Solid_Second-Quarter_Financial_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Solid_Second-Quarter_Financial_Results/</comments>
<pubDate>Sun, 26 Jul 2009 14:00:21 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Solid_Second-Quarter_Financial_Results/</guid>
<description><![CDATA[Genzyme Corp. (NASDAQ: GENZ) reported that second-quarter revenue rose to $1.23 billion, compared with $1.17 billion in the same period a year ago, an increase of 5 percent. Including the $66 million<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Reports Second-Quarter 2009 Revenues of $11.0 Billion]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Second-Quarter_2009_Revenues_of_11-0_Billion/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Second-Quarter_2009_Revenues_of_11-0_Billion/</comments>
<pubDate>Sun, 26 Jul 2009 14:00:08 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Reports_Second-Quarter_2009_Revenues_of_11-0_Billion/</guid>
<description><![CDATA[Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2009. Revenues were $11.0 billion, a decrease of 9% compared with the year-ago quarter and flat on a constant currency basis. For<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis delivers strong operational performance in the first half of 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_operational_performance_in_the_first_half_of_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_operational_performance_in_the_first_half_of_2009/</comments>
<pubDate>Wed, 22 Jul 2009 10:15:44 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_delivers_strong_operational_performance_in_the_first_half_of_2009/</guid>
<description><![CDATA[- Pharmaceuticals an industry growth leader: Net sales up 12% (local currencies) in first half of 2009 on contributions from new products and expansion in all regions- R&amp;D maintains momentum: Anti-<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Reports Strong Second Quarter Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Reports_Strong_Second_Quarter_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Reports_Strong_Second_Quarter_Results/</comments>
<pubDate>Fri, 17 Jul 2009 22:33:17 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Reports_Strong_Second_Quarter_Results/</guid>
<description><![CDATA[Abbott (NYSE: ABT) has announced financial results for the second quarter ended June 30, 2009. Diluted earnings per share, excluding specified items, were $0.89, at the high end of Abbott's second-q<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer acquires exclusive rights to Bioton's insulin SciLin]]></title>
<link>http://www.worldpharmanews.net/Financial/Bayer_acquires_exclusive_rights_to_Biotons_insulin_SciLin%AE/</link>
<comments>http://www.worldpharmanews.net/Financial/Bayer_acquires_exclusive_rights_to_Biotons_insulin_SciLin%AE/</comments>
<pubDate>Mon, 13 Jul 2009 10:09:16 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Bayer_acquires_exclusive_rights_to_Biotons_insulin_SciLin%AE/</guid>
<description><![CDATA[Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton's Singaporean subsidiary, SciGen, to strengthen i<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sandoz to acquire EBEWE Pharma specialty generics business]]></title>
<link>http://www.worldpharmanews.net/Financial/Sandoz_to_acquire_EBEWE_Pharma_specialty_generics_business/</link>
<comments>http://www.worldpharmanews.net/Financial/Sandoz_to_acquire_EBEWE_Pharma_specialty_generics_business/</comments>
<pubDate>Mon, 25 May 2009 00:19:40 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Sandoz_to_acquire_EBEWE_Pharma_specialty_generics_business/</guid>
<description><![CDATA[Novartis has signed a definitive agreement to acquire the specialty generic injectables business of EBEWE Pharma, providing Sandoz - the Group's generic pharmaceuticals division - an opportunity to <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Q1/2009: Merck Revenues Remain Stable at  1.9 Billion]]></title>
<link>http://www.worldpharmanews.net/Financial/Q12009_Merck_Revenues_Remain_Stable_at_%C2%80_1-9_Billion/</link>
<comments>http://www.worldpharmanews.net/Financial/Q12009_Merck_Revenues_Remain_Stable_at_%C2%80_1-9_Billion/</comments>
<pubDate>Thu, 30 Apr 2009 00:27:50 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Q12009_Merck_Revenues_Remain_Stable_at_%C2%80_1-9_Billion/</guid>
<description><![CDATA[All in all, the Merck Group performed solidly during the first quarter of 2009. However, Merck is not an island. The recession is affecting the company's results, mainly in the Chemicals business se<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Reports First-Quarter 2009 Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2009_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2009_Results/</comments>
<pubDate>Wed, 29 Apr 2009 01:29:12 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2009_Results/</guid>
<description><![CDATA[Pfizer Inc (NYSE: PFE) has reported financial results for first-quarter 2009. Revenues were $10.9 billion, a decrease of 8% compared with the year-ago quarter. Foreign exchange unfavorably impacted r<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis expects strong operational performance in 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_expects_strong_operational_performance_in_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_expects_strong_operational_performance_in_2009/</comments>
<pubDate>Tue, 28 Apr 2009 00:40:31 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_expects_strong_operational_performance_in_2009/</guid>
<description><![CDATA[Pharmaceuticals delivers strong underlying growth in first quarter of 2009 as Novartis continues to rejuvenate product portfolio. Group's strong operational performance led by Pharmaceuticals net sa<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Reports Solid Financial Results for the First Quarter of 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Solid_Financial_Results_for_the_First_Quarter_of_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Solid_Financial_Results_for_the_First_Quarter_of_2009/</comments>
<pubDate>Sat, 25 Apr 2009 00:04:09 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Solid_Financial_Results_for_the_First_Quarter_of_2009/</guid>
<description><![CDATA[Genzyme Corp. (NASDAQ: GENZ) reported that first-quarter revenue rose to $1.15 billion, compared with $1.10 billion in the same period a year ago, an increase of 4 percent. Including the $66 million <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche strongly outperforms market in first quarter]]></title>
<link>http://www.worldpharmanews.net/Financial/Roche_strongly_outperforms_market_in_first_quarter/</link>
<comments>http://www.worldpharmanews.net/Financial/Roche_strongly_outperforms_market_in_first_quarter/</comments>
<pubDate>Thu, 23 Apr 2009 00:03:26 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roche_strongly_outperforms_market_in_first_quarter/</guid>
<description><![CDATA[The Roche Group recorded total sales of 11.6 billion Swiss francs in the first quarter of 2009, an increase of 8% in local currencies (7% in Swiss francs; -1% in US dollars)1 compared with the year-e<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company]]></title>
<link>http://www.worldpharmanews.net/Financial/Sanofi-aventis_to_acquire_BiPar_Sciences_a_US_biopharmaceutical_company/</link>
<comments>http://www.worldpharmanews.net/Financial/Sanofi-aventis_to_acquire_BiPar_Sciences_a_US_biopharmaceutical_company/</comments>
<pubDate>Wed, 22 Apr 2009 00:12:36 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Sanofi-aventis_to_acquire_BiPar_Sciences_a_US_biopharmaceutical_company/</guid>
<description><![CDATA[Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has signed a binding agreement for the acquisition of BiPar Sciences, Inc., (&quot;BiPar&quot;) a privately held US biopharmaceutical company, developing novel tu<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Reports 16 Percent Earnings Growth in First Quarter]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Reports_16_Percent_Earnings_Growth_in_First_Quarter/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Reports_16_Percent_Earnings_Growth_in_First_Quarter/</comments>
<pubDate>Mon, 20 Apr 2009 00:53:25 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Reports_16_Percent_Earnings_Growth_in_First_Quarter/</guid>
<description><![CDATA[Abbott has announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above t<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche Diabetes Care supports &quot;Changing Diabetes in Children&quot;]]></title>
<link>http://www.worldpharmanews.net/Financial/Roche_Diabetes_Care_supports_Changing_Diabetes_in_Children/</link>
<comments>http://www.worldpharmanews.net/Financial/Roche_Diabetes_Care_supports_Changing_Diabetes_in_Children/</comments>
<pubDate>Sat, 18 Apr 2009 22:06:05 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roche_Diabetes_Care_supports_Changing_Diabetes_in_Children/</guid>
<description><![CDATA[Roche will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk's five-year program called &quot;Changing Diabetes in Children&quot;. Roche Diabetes Care will actively endor<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Annual General Meeting of Merck KGaA: Shareholders Approve Dividend of a4 1.50 per Share]]></title>
<link>http://www.worldpharmanews.net/Financial/Annual_General_Meeting_of_Merck_KGaA_Shareholders_Approve_Dividend_of_euro_1-50_per_Share/</link>
<comments>http://www.worldpharmanews.net/Financial/Annual_General_Meeting_of_Merck_KGaA_Shareholders_Approve_Dividend_of_euro_1-50_per_Share/</comments>
<pubDate>Tue, 07 Apr 2009 00:59:14 EEST</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Annual_General_Meeting_of_Merck_KGaA_Shareholders_Approve_Dividend_of_euro_1-50_per_Share/</guid>
<description><![CDATA[Shareholders of Merck KGaA approved a dividend of € 1.50 per share for 2008 at the company's Annual General Meeting held at the Jahrhunderthalle in Frankfurt. This corresponds to an increase of 25% <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Merck and Schering-Plough to Merge]]></title>
<link>http://www.worldpharmanews.net/Financial/Merck_and_Schering-Plough_to_Merge/</link>
<comments>http://www.worldpharmanews.net/Financial/Merck_and_Schering-Plough_to_Merge/</comments>
<pubDate>Wed, 11 Mar 2009 09:28:20 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Merck_and_Schering-Plough_to_Merge/</guid>
<description><![CDATA[Merck &amp; Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Scheri<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009]]></title>
<link>http://www.worldpharmanews.net/Financial/Lundbeck_meets_all_of_its_financial_forecasts_for_2008_and_expects_continuing_growth_in_2009/</link>
<comments>http://www.worldpharmanews.net/Financial/Lundbeck_meets_all_of_its_financial_forecasts_for_2008_and_expects_continuing_growth_in_2009/</comments>
<pubDate>Fri, 06 Mar 2009 00:05:05 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Lundbeck_meets_all_of_its_financial_forecasts_for_2008_and_expects_continuing_growth_in_2009/</guid>
<description><![CDATA[Lundbeck has presented annual accounts in which all of the financial results meet the financial guidance announced by the company in March 2008. For the first time ever, revenue exceeded DKK 11 billi<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The Bayer Group achieved its earnings targets for 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/The_Bayer_Group_achieved_its_earnings_targets_for_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/The_Bayer_Group_achieved_its_earnings_targets_for_2008/</comments>
<pubDate>Fri, 06 Mar 2009 00:04:54 EET</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/The_Bayer_Group_achieved_its_earnings_targets_for_2008/</guid>
<description><![CDATA[&quot;From an operational standpoint, 2008 was the most successful year in Bayer's long history,&quot; said Management Board Chairman Werner Wenning on Tuesday at the Spring Financial News Conference in Lev<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration-1/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration-1/</comments>
<pubDate>Tue, 03 Mar 2009 00:06:33 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration-1/</guid>
<description><![CDATA[AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulat<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Successfully_Completes_Tender_Offer_for_Shares_of_Advanced_Medical_Optics/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Successfully_Completes_Tender_Offer_for_Shares_of_Advanced_Medical_Optics/</comments>
<pubDate>Fri, 27 Feb 2009 00:01:54 EET</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Successfully_Completes_Tender_Offer_for_Shares_of_Advanced_Medical_Optics/</guid>
<description><![CDATA[Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced M<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed reports a satisfactory 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Nycomed_reports_a_satisfactory_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Nycomed_reports_a_satisfactory_2008/</comments>
<pubDate>Wed, 25 Feb 2009 00:03:22 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Nycomed_reports_a_satisfactory_2008/</guid>
<description><![CDATA[For Nycomed the twelve months of 2008 have been satisfactory and most of the markets performed well and met expectations. Key products developed strongly, with the exception of Pantoprazole sales in <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Merck: 2008 Operating Result Rises 16% to a4 1,131 Million]]></title>
<link>http://www.worldpharmanews.net/Financial/Merck_2008_Operating_Result_Rises_16_to_euro_1131_Million/</link>
<comments>http://www.worldpharmanews.net/Financial/Merck_2008_Operating_Result_Rises_16_to_euro_1131_Million/</comments>
<pubDate>Thu, 19 Feb 2009 00:15:34 EET</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Merck_2008_Operating_Result_Rises_16_to_euro_1131_Million/</guid>
<description><![CDATA[Despite a rapidly deteriorating economic situation, total revenues of the Merck Group rose 7.1% to a record € 7,558 million in 2008 due to increased sales of Pharmaceuticals and a 26% increase in roy<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
